ARE THE CLOUDS CLEARING OVER THE 2018 TAX SEASON?
- A+T
- Feb 7, 2023
- 1 min read
With the partial government shutdown last month and the possibility of another shutdown looming, there has been a lot of talk about the IRS and filing taxes for 2018. Regardless if lawmakers pass a budget in the coming weeks and keep the government open or not, tax laws remain in effect and deadlines stay the same. The IRS has said that tax returns will be processed and tax refunds will be issued regardless of a government shutdown.
Upcoming dates to remember:
Deadline : March 15, 2019
Tax filing deadline for S corporations (Form 1120-S)
Tax filing deadline for Partnerships (Form 1065)
S corporations and Partnerships NOT filing by this deadline will need to file for an extension by March 15, 2019.
Deadline : April 15, 2019
Tax filing deadline for individuals (Forms 1040, 1040A, or 1040EZ)
Tax filing deadline for Corporations (Form 1120)
If you pay taxes on a quarterly basis, the first estimated quarterly tax payment for 2019 is due April 15, 2019.
Individuals and Corporations NOT filing by this deadline will need to file for an extension by April 15, 2019.
Deadline : June 15, 2019
If you pay taxes on a quarterly basis, the second estimated quarterly tax payment for 2019 is due June 15, 2019.
Excellent writeup — exactly what I was looking for!
The mechanism behind GLP-1 therapy is fascinating from a physiological standpoint. Glucagon-like peptide-1 is an incretin hormone naturally secreted by L-cells in the small intestine in response to food intake. It acts on pancreatic beta cells to enhance insulin secretion, suppresses glucagon release, and crucially, signals satiety to the hypothalamus. Synthetic GLP-1 receptor agonists mimic and amplify these effects, providing sustained appetite suppression and improved glycemic control that diet alone simply cannot achieve for many patients. This dual action on both blood sugar regulation and body weight makes these compounds uniquely valuable in treating the overlapping epidemics of obesity and type 2 diabetes.
Access and affordability remain significant challenges in the…